HopeStage
Back to all studies
CompletedNCT01031927

Sarcosine for obsessive-compulsive disorder

About this title

N-methyl Glycine (Sarcosine) for the Treatment of Obsessive Compulsive Disorder (OCD)

Read the official source — NCT01031927
Medication studyAges 18–65TaiwanOCD
The study in practice

Understand this study

Who was this study for?

This study was for people with OCD. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
TaichungSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJune 2007
Recruitment status
Completed
Enrollment listed in the registry
30
Sponsor
China Medical University Hospital
Sponsor type
Hospital / academic medical center
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Taiwan
Age range
From 18 Years to 65 Years
Official registry ID
NCT01031927
Official title
Show the full official title

Sarcosine as Primary or Adjunctive Therapy in Obsessive Compulsive Disorder: A Prospective, Open-label Study

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Taichung

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is China Medical University Hospital, a hospital or academic medical center.

Did this study involve medication?

Yes. The study involved medication, including N-methyl glycine.

Who was this study for?

This study was for people with OCD. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies